{
    "nct_id": "NCT03646162",
    "official_title": "Randomized, Double-blind, Placebo Controlled, Dose Finding Phase 2 Study Comparing Oral Daily Dosing of VERU-944 to Ameliorate the Vasomotor Symptoms Resulting From ADT in Men With Advanced Prostate Cancer",
    "inclusion_criteria": "Inclusion Criteria\n\n1. Be over 18 years of age;\n2. Be able to communicate effectively with the study personnel;\n3. Have histologically confirmed prostate cancer;\n4. Have been treated with an LHRH agonist or LHRH antagonist for at least the 3 months prior to randomization;\n5. Be continued on an LHRH agonist or LHRH antagonist throughout this study;\n6. Have experienced hot flashes for at least one month prior to study entry;\n7. Have moderate or severe vasomotor symptoms (hot flashes) (defined as a minimum of 4 moderate to severe hot flashes per day or 12 per week at baseline);\n8. ECOG performance status of 0 to 2\n9. Be willing to uses electronic data capture for the relevant medical events\n\n   â€¢ Must be at least 80% compliant during the screening period\n10. Subjects must agree to use acceptable methods of contraception:\n\n    * If their female partners are pregnant or lactating, acceptable methods of contraception from the time of the first administration of study medication until 6 months following administration of the last dose of study medication must be used. Acceptable methods are: Condom used with spermicidal foam/gel/film/cream/suppository. If the subject has undergone surgical sterilization (vasectomy with documentation of azospermia), a condom with spermicidal foam/gel/film/cream/suppository should be used.\n    * If the male subject's partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 6 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/film/cream/suppository [i.e., barrier method of contraception], surgical sterilization (vasectomy with documentation of azospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam/gel/film/cream/suppository).\n    * If the female partner has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam/gel/film/cream/suppository) should also be used.\n    * If the female partner has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam/gel/film/cream/suppository) should also be used.\n11. Subject is willing to comply with the requirements of the protocol through the end of the study.\n\nExclusion Criteria\n\n1. Have a serum total testosterone concentration > 50 ng/dL at screening;\n2. Known hypersensitivity or allergy to estrogen or estrogen like drugs;\n3. Any disease or condition (medical or surgical) which might compromise the hematologic, cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk;\n4. Subjects with a personal history of abnormal blood clotting or thrombotic disease, including venous or arterial thrombotic events such as a history of stroke, deep vein thrombosis (DVT), and/or pulmonary embolus (PE);\n5. Any subjects, as determined by a central laboratory, that have a:\n\n   * Factor V Leiden gene mutation\n   * Prothrombin gene mutation\n6. Uncontrolled symptomatic congestive heart failure (NYHA Class III - IV), unstable angina pectoris, cardiac arrhythmia, or uncontrolled atrial fibrillation;\n7. History of MI\n8. The presence of consistently abnormal laboratory values which are considered clinically significant. In addition, any subject with liver enzymes (ALT or AST) above 2 times the upper limit of normal, total bilirubin above 2 times the upper limit of normal, or serum creatinine above 1.5 times the upper limit of normal will NOT be admitted to the study;\n9. Received an investigational drug within a period of 90 days prior to enrollment in the study;\n10. Received the study medication (VERU-944) previously;\n11. Have previously taken within 6 months prior to screening or are currently taking diethylstilbestrol, other estrogens;\n12. Currently taking gabapentin, estrogen, diethylstilbestrol, medroxyprogesterone acetate, clomiphene, selective serotonin reuptake inhibitors (SSRIs), other treatments for hot flashes\n13. Recent hospitalization for more than 24 hours (within 30 days of screening);\n14. Recent surgery (within 30 days of screening);\n15. Have been previously diagnosed or treated for active cancer (other than prostate cancer or non-melanoma skin cancer) within the previous five years;\n16. Have a BMI >40.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}